title: The role of radiation therapy in the treatment of stage I-II diffuse large B-cell lymphoma.
abstract: The role of radiation therapy (RT) in the treatment of Stage I-II diffuse large B cell lymphoma (DLBCL) is controversial: consolidation RT improves local control, but does this translate into an overall survival benefit? The paucity of randomized clinical trials means that the debate surrounding the benefit of consolidation RT remains unresolved. To date, the published literature demonstrates that consolidation RT has dual advantages in patients stage I-II DLBCL: (1) to improve local control and progression-free survival, and (2) to spare additional cycles of chemotherapy in patient with favourable-risk disease. Critics of consolidation RT are often influenced by the profile of late toxicities that are associated with outdated RT techniques. In the current era of molecular-based targeted therapy and functional imaging, prospective randomized studies are required to answer this research question and to investigate risk-adapted treatment strategies for patients with stage I-II DLBCL.
authors.affiliation: Department of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. Belinda.Campbell@petermac.org
authors.forename: Belinda A
authors.initials: BA
authors.lastname: Campbell
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D064847:Multimodal Imaging / Q000379:methods; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
references.citation: Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):563-8
references.pmid: 10348285
references.citation: Cancer. 2012 Sep 1;118(17):4156-65
references.pmid: 22252721
references.citation: J Clin Oncol. 2007 Mar 1;25(7):787-92
references.pmid: 17228021
references.citation: J Nucl Med. 2011 Mar;52(3):386-92
references.pmid: 21321279
references.citation: Semin Radiat Oncol. 2007 Jul;17(3):169-75
references.pmid: 17591563
references.citation: Leuk Lymphoma. 2009 Nov;50(11):1753-6
references.pmid: 19863178
references.citation: Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1465-71
references.pmid: 18495371
references.citation: Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):507-12
references.pmid: 20056353
references.citation: Hematol Oncol Clin North Am. 2008 Oct;22(5):941-52, ix
references.pmid: 18954744
references.citation: Ann Oncol. 2012 May;23(5):1259-1266
references.pmid: 21980193
references.citation: J Natl Compr Canc Netw. 2010 Mar;8(3):288-334
references.pmid: 20202462
references.citation: Leuk Lymphoma. 2007 Nov;48(11):2121-36
references.pmid: 17990176
references.citation: N Engl J Med. 1998 Jul 2;339(1):21-6
references.pmid: 9647875
references.citation: Blood. 2004 Feb 15;103(4):1222-8
references.pmid: 14576060
references.citation: J Clin Oncol. 2006 Jul 1;24(19):3121-7
references.pmid: 16754935
references.citation: J Clin Oncol. 2008 May 10;26(14):2258-63
references.pmid: 18413640
references.citation: Curr Opin Oncol. 2009 Sep;21(5):401-6
references.pmid: 19593138
references.citation: Leuk Lymphoma. 2008 Apr;49(4):663-76
references.pmid: 18398733
references.citation: J Clin Oncol. 2002 Jan 1;20(1):197-204
references.pmid: 11773170
references.citation: J Clin Oncol. 2010 Sep 20;28(27):4105-7
references.pmid: 20713874
references.citation: N Engl J Med. 2002 Jan 24;346(4):235-42
references.pmid: 11807147
references.citation: Ann Oncol. 2012 Oct;23 Suppl 7:vii78-82
references.pmid: 22997459
references.citation: Lancet Oncol. 2006 May;7(5):379-91
references.pmid: 16648042
references.citation: Curr Opin Oncol. 2010 Sep;22(5):414-8
references.pmid: 20683268
references.citation: Leuk Lymphoma. 2003 Sep;44(9):1535-9
references.pmid: 14565656
references.citation: Leuk Lymphoma. 2013 Dec;54(12):2631-8
references.pmid: 23488661
references.citation: J Clin Oncol. 2010 Sep 20;28(27):4170-6
references.pmid: 20713859
references.citation: J Clin Oncol. 2008 Nov 10;26(32):5170-4
references.pmid: 18838714
references.citation: Expert Rev Anticancer Ther. 2011 Sep;11(9):1367-78
references.pmid: 21929311
references.citation: N Engl J Med. 2005 Mar 24;352(12):1197-205
references.pmid: 15788496
references.citation: Hematology Am Soc Hematol Educ Program. 2012;2012:397-401
references.pmid: 23233610
references.citation: J Clin Oncol. 2004 Aug 1;22(15):3032-8
references.pmid: 15210738